homepage-top-section

The trial is one of the two phase 1 safety clinical studies of the drug examining its potential to cause dermal irritation. XF-73 is Destiny Pharma’s lead candidate

The company will build the new multi-storey and 400,000ft² production facility in Portage, situated in Kalamazoo County. Named as modular aseptic processing (MAP), the new production facility will

The chemotherapy used in combination with Tecentriq is Abraxane [albumin-bound paclitaxel; nab-paclitaxel]). The late-stage trial dubbed IMpassion130 was found to have reduced the risk of disease worsening or

The companies announced that they had entered into exclusive talks on April 17, 2018. The signing of this Share Purchase Agreement marks a critical step on the way

Based on the results of this analysis, the DRC determined that the trial was futile, meaning that it was not likely to meet its primary end-point upon completion